Krystal Biotech Inc (KRYS) Stock Price, Quote & News

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 586 5830

Website: www.krystalbio.com

Address:

2100 Wharton Street, Suite 701, Pittsburgh, United States

1GreenDay99RedDays Mar. 2 at 8:43 PM

$KRYS been a monster for 5 years i comment and blamo

0 · Reply

GorillaTrades Feb. 27 at 8:22 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Cboe Global Markets $CBOE +4.7%, Krystal Biotechnology $KRYS +4.7%, and Agree Realty $ADC +3.5%

0 · Reply

OfficialStocktwitsUser Feb. 25 at 10:34 PM

$KRYS RSI: 52.04, MACD: 1.0698 Vol: 6.74, MA20: 273.76, MA50: 265.48 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

erevnon Feb. 25 at 2:57 PM

Guggenheim maintains Krystal Biotech $KRYS at Buy and raises the price target from $224 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Theflash88 Feb. 22 at 9:01 PM

$KRYS Well that big rally didn’t last long.

0 · Reply

wheresdannynow Feb. 20 at 8:22 PM

$KRYS is crushing it with Vyjuvek sales and pipeline wins. That’s what biotech patience looks like when it pays. While big caps like $LLY $NVO stay crowded, small caps can reprice hard when data lines up. $BIOV.CSE $BVAXF quietly stacking positive DPX data in ovarian, bladder, and breast cancer. Platform stories heat up fast once momentum builds. Biotech does not reward panic. It rewards positioning.

0 · Reply

Ventureville Feb. 20 at 3:57 PM

Q1 2026 is already lighting up biotech. $MBRX accelerating its AML trial. $KRYS beating on earnings. Multiple FDA decisions lined up across the sector. When biotech momentum builds, small caps move fast. $BIOV.CSE $BVAXF with HapTenix and BVX-0918 in ovarian cancer sits right in that wave. Rotation into biotech does not trickle. It snaps.

0 · Reply

erevnon Feb. 18 at 7:31 PM

Citigroup maintains Krystal Biotech $KRYS at Buy and raises the price target from $336 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 18 at 5:08 PM

$KRYS just delivered an earnings twist — beat on EPS, miss on revenue. So what really matters here? 👀 KRYS topped Q4 estimates while Vyjuvek sales jumped 17%, locked in 660+ U.S. reimbursements, and pushed its gene therapy pipeline runway into 2026. That’s operational momentum, even with revenues missing the mark. Is this a setup for longer-term upside or a mixed signal? Get the full breakdown 👉 https://www.zacks.com/stock/news/2871431/krystal-biotech-q4-earnings-beat-estimates-revenues-miss-mark?cid=sm-stocktwits-2-2871431-teaser-34052&ADID=SYND_STOCKTWITS_TWEET_2_2871431_TEASER_34052

0 · Reply

ZacksResearch Feb. 18 at 4:08 PM

$KRYS earnings beat! 🚀 What drove the growth? Krystal Biotech's Q4 EPS of $1.70 beat the Zacks Consensus Estimate of $1.62, with revenue up 17.5% in the reported quarter, thanks to strong Vyjuvek sales. The stock is up 63.4% over the past year! 📈 Find out what’s next for KRYS here 👉 https://www.zacks.com/stock/news/2871431/krystal-biotech-q4-earnings-beat-estimates-revenues-miss-mark?cid=sm-stocktwits-2-2871431-body-34049&ADID=SYND_STOCKTWITS_TWEET_2_2871431_BODY_34049

0 · Reply

Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 3:02 PM EST - 20 days ago

Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology

Feb 17, 2026, 7:00 AM EST - 21 days ago

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 1:41 PM EST - 4 weeks ago

Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update

Feb 10, 2026, 8:00 AM EST - 4 weeks ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 16, 2026, 7:45 AM EST - 7 weeks ago

Krystal Biotech: Beyond VYJUVEK Commercialization

Jan 15, 2026, 10:31 AM EST - 7 weeks ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Jan 12, 2026, 12:16 PM EST - 2 months ago

Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 1:00 PM EST - 2 months ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 2:14 AM EST - 2 months ago

Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript

Nov 26, 2025, 8:00 AM EST - 3 months ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Nov 16, 2025, 9:00 AM EST - 4 months ago

Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth

Nov 3, 2025, 5:17 PM EST - 4 months ago

Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade)

Nov 3, 2025, 11:46 AM EST - 4 months ago

Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

Sep 15, 2025, 1:39 PM EDT - 6 months ago

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

Sep 15, 2025, 8:00 AM EDT - 6 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Aug 22, 2025, 2:41 PM EDT - 7 months ago

Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update

Aug 21, 2025, 12:11 PM EDT - 7 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 4, 2025, 12:42 PM EDT - 7 months ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Jul 25, 2025, 9:00 AM EDT - 8 months ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 24, 2025, 8:00 AM EDT - 8 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jun 24, 2025, 7:00 AM EDT - 9 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

May 7, 2025, 8:00 AM EDT - 10 months ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 2:43 PM EDT - 11 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 7:00 AM EDT - 11 months ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK

Feb 28, 2025, 7:40 AM EST - 1 year ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 21, 2025, 8:15 AM EST - 1 year ago

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus

Feb 19, 2025, 11:43 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jan 14, 2025, 8:00 AM EST - 1 year ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Dec 27, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 18, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 9, 2024, 4:15 PM EST - 1 year ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 6, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2024, 3:31 PM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 14, 2024, 4:58 PM EDT - 1 year ago

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:10 PM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 11:13 PM EDT - 1 year ago

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 26, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

May 15, 2024, 8:08 AM EDT - 1 year ago

Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB

May 15, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

1GreenDay99RedDays Mar. 2 at 8:43 PM

$KRYS been a monster for 5 years i comment and blamo

0 · Reply

GorillaTrades Feb. 27 at 8:22 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Cboe Global Markets $CBOE +4.7%, Krystal Biotechnology $KRYS +4.7%, and Agree Realty $ADC +3.5%

0 · Reply

OfficialStocktwitsUser Feb. 25 at 10:34 PM

0 · Reply

erevnon Feb. 25 at 2:57 PM

Guggenheim maintains Krystal Biotech $KRYS at Buy and raises the price target from $224 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Theflash88 Feb. 22 at 9:01 PM

$KRYS Well that big rally didn’t last long.

0 · Reply

wheresdannynow Feb. 20 at 8:22 PM

0 · Reply

Ventureville Feb. 20 at 3:57 PM

0 · Reply

erevnon Feb. 18 at 7:31 PM

Citigroup maintains Krystal Biotech $KRYS at Buy and raises the price target from $336 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 18 at 5:08 PM

0 · Reply

ZacksResearch Feb. 18 at 4:08 PM

0 · Reply

erevnon Feb. 18 at 2:25 PM

Chardan Capital maintains Krystal Biotech $KRYS at Buy and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

mikesterz7 Feb. 17 at 8:49 PM

$KRYS Krystal’s Vyjuvek is a gene therapy approved for the treatment of Dystrophic Epidermolysis Bullosa.

0 · Reply

StocktwitsNews Feb. 17 at 8:21 PM

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism $KRYS $IJR $VTI https://stocktwits.com/news/equity/markets/krys-stock-rallies-on-upbeat-earnings-jefferies-ups-price-target/cZRWvWzR4HT

0 · Reply

1GreenDay99RedDays Feb. 17 at 6:57 PM

$KRYS honestly i cant think of a better looking chart in all of biotech than this, i made money here in 2021 and sold like a stunad congrats to all

0 · Reply

GitRichOrBuyTryin Feb. 17 at 4:52 PM

$KRYS - Bought KRYS at $290 IBD buy point triggered at $286.52

0 · Reply

d_risk Feb. 17 at 4:43 PM

$KRYS - Krystal Biotech Inc - 10K - Updated Risk Factors KRYS’s 2026 10-K sharpens risk around VYJUVEK dependence, global gene therapy commercialization and manufacturing scale-up (including ASTRA), intensifies focus on pricing/reimbursement, IP and patent litigation, cybersecurity and a 2024 incident, AI and data privacy laws, while adding detailed global regulatory, quality, executive loss, and capital/ownership concentration risks. #GeneTherapy #ManufacturingScale-Up #PricingRisk #IPLitigation #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/KRYS/10-K/2026-02-17

0 · Reply

OpenOutcrier Feb. 17 at 1:59 PM

$KRYS (-1.2% pre) Krystal Biotech beats top-line and bottom-line estimates; initiates FY26 outlook https://ooc.bz/l/93538

0 · Reply

DonCorleone77 Feb. 17 at 12:30 PM

$KRYS Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M

0 · Reply

DonCorleone77 Feb. 17 at 12:29 PM

$KRYS Krystal Biotech reports Q4 EPS $1.70, consensus $1.61 Reports Q4 revenue $107.1M, consensus $105.13M. "In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact," said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. "As we work toward our goal of launching multiple products and treating more than 10,000 patients living with rare diseases by the end of 2030, our recent cystic fibrosis readout further reinforces the versatility of our platform in high-turnover epithelial tissues. We believe we are still in the early stages of unlocking the transformational potential of our redosable HSV-1-based gene delivery platform, and we look forward to multiple registrational study readouts ahead across our rare disease pipeline."

0 · Reply

StocktwitsEarnings Feb. 17 at 12:13 PM

$KRYS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.77 up 12.03% YoY • Reported revenue of $107.11M up 17.52% YoY • Krystal Biotech, Inc. expects pricing negotiations for VYJUVEK in Germany and France to continue until at least H2 2026 and 2027, respectively, with a potential Italian launch in H2 2026. Krystal Biotech, Inc. also anticipates initiating a Phase 2 study for KB304 in 2027.

0 · Reply

Florestan Feb. 17 at 5:50 AM

$MSLE if you're bitter and you're bashing because you missed the boat, guess what? You haven't. A disease modifying drug for DMD would be worth billions. Look at Avidity. Look at Sarepta when the world thought their drug would work. Look at $KRYS, perennial buyout target after having a disease modifying drug for DEB. This is just the beginning for Satellos.

0 · Reply

eWhispers Feb. 16 at 3:33 PM

#earnings before the open on Tuesday, February 17, 2026 https://www.earningswhispers.com/calendar $ET $MDT $LDOS $KRYS $ETOR

1 · Reply

Market Cap	7.42B
Revenue (ttm)	389.13M
Net Income (ttm)	204.83M
EPS (ttm)	N/A
PE Ratio	38.00
Forward PE	32.20
Profit Margin	52.64%
Debt to Equity Ratio	0.00

Volume	148,760
Avg Vol	294,532
Day's Range	N/A - N/A
Shares Out	29.23M
Stochastic %K	29%
Beta	0.49
Analysts	Strong Sell
Price Target	$324.30